Blood Brain Barrier Shuttle Using Transferrin Receptor Mediator
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for delivering neurological disorder drugs across the blood-brain barrier (BBB) face challenges in maximizing brain uptake while minimizing miss-sorting within brain endothelial cells and accumulation in degradative organelles.
Innovation Solution
A blood brain barrier shuttle comprising a full-length IgG antibody directed to a brain antigen, a linker, and one scFab directed to the transferrin receptor, where the scFab is coupled to the C-terminal end of the Fc part of the IgG antibody, recognizing specific epitopes on the transferrin receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to cross the BBB, then therapeutic potential is achieved, but brain penetration is limited to approximately 0.1%
Solution Approach 1:
The patent uses the transferrin receptor (TfR) as an intermediary mediator to facilitate antibody transport across the BBB. The antibody is engineered to bind TfR on the luminal side of brain capillary endothelial cells, utilizing the receptor's natural transcytosis function to shuttle the antibody across the barrier and into the brain parenchyma, thereby overcoming the passive penetration limitation.
Solution Approach 2:
The patent fundamentally changes the transport parameter from passive diffusion (0.1% penetration) to active receptor-mediated transcytosis. By modifying the antibody structure to include TfR binding capability and utilizing the cellular transport machinery, the brain penetration efficiency is dramatically enhanced while maintaining therapeutic function.
2Quantity of substance
If receptor-mediated delivery strategies are used, then brain uptake is maximized, but miss-sorting within brain endothelial cells and accumulation in degradative organelles occurs
Solution Approach 1:
The patent applies local quality by creating an asymmetric antibody structure where only one arm (scFab) binds to the transferrin receptor while the other arm retains the full antibody's therapeutic function. This localized binding approach ensures that the antibody engages TfR for transport without triggering the cellular sorting pathways that lead to lysosomal degradation, thereby maintaining both high brain uptake and therapeutic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The shuttle effectively crosses the BBB, achieving a significant increase in brain exposure and plaque decoration, with the single Fab construct showing a 55-fold higher plaque decoration compared to the parent IgG antibody, while maintaining normal trafficking of the transferrin receptor.
Implementation Method 1
strategies to maximize brain uptake while minimizing miss-sorting within the brain endothelial cells (BECs), and the extent of accumulation within certain organelles (especially organelles that leads to degradation of the biotherapeutic) in BECs, remain unexplored
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The present disclosure relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same.